HeartBeam, Inc.

Snapshot

HeartBeam is a pre-revenue medical device company: $0 in revenue for three straight fiscal years alongside a $21.0M net loss in FY 2025. It holds $8.7M in cash with no debt, but Signal8 models roughly 4.3 months of runway.

What's Happening Right Now

• Mon 5th Oct '26 · FDA designation: HeartBeam received FDA Breakthrough Device Designation for its system's use in assessing potential heart attacks at home, ahead of a planned larger clinical study.
• Tue 22nd Sep '26 · Strategy shift: HeartBeam said it will stop building a large sales team for its cleared arrhythmia product and redirect resources toward heart-attack detection, citing pilot study data and an FDA pre-submission filed in August.
• Wed 9th Sep '26 · Going concern: HeartBeam's 10-Q disclosed zero revenue in Q2 2026 and said its $8.7M cash balance raises substantial doubt about continuing as a going concern; the former CEO departed and a director resigned amid a strategic shift toward licensing.
• Wed 9th Sep '26 · ATM offering: HeartBeam filed a $25M at-the-market stock sale program that, if fully used, could add roughly 42.4 million new shares versus 56.3 million outstanding.
• Tue 14th Jul '26 · Patent: HeartBeam was awarded a new U.S. patent adding acoustic sensing and fluid-monitoring capabilities to its cable-free ECG device, its 26th issued patent.
• Tue 30th Jun '26 · Offering: Closed a block sale under its at-the-market program. Proceeds are not disclosed in the filings reviewed.
• Thu 7th May '26 · Warrants: Issued warrants over 719K shares.
• Thu 16th Apr '26 · Offering: Raised $11.50M in gross proceeds through a public offering.